Hyperlipidemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Hyperlipidemia - Pipeline Review, H2 2016

Hyperlipidemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Hyperlipidemia - Pipeline Review, H2 2016
Published Aug 10, 2016
209 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hyperlipidemia - Pipeline Review, H2 2016, provides an overview of the Hyperlipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
- The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects
- The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hyperlipidemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
- Develop an

  
Source:
Document ID
GMDHC8344IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Hyperlipidemia Overview131
Therapeutics Development142
  Pipeline Products for Hyperlipidemia Overview141
  Pipeline Products for Hyperlipidemia Comparative Analysis151
Hyperlipidemia Therapeutics under Development by Companies164
Hyperlipidemia Therapeutics under Investigation by Universities/Institutes201
Hyperlipidemia Pipeline Products Glance214
  Late Stage Products211
  Clinical Stage Products221
  Early Stage Products231
  Unknown Stage Products241
Hyperlipidemia Products under Development by Companies253
Hyperlipidemia Products under Investigation by Universities/Institutes281
Hyperlipidemia Companies Involved in Therapeutics Development2936
  Acasti Pharma Inc.291
  Akcea Therapeutics Inc301
  Allergan Plc311
  Alnylam Pharmaceuticals, Inc.321
  Amgen Inc.331
  Arisaph Pharmaceuticals, Inc.341
  AstraZeneca Plc351
  BASF SE361
  BCWorld Pharm Co. Ltd.371
  BioRestorative Therapies, Inc.381
  Cadila Pharmaceuticals Limited391
  Cardax Pharmaceuticals, Inc.401
  Catabasis Pharmaceuticals, Inc.411
  CJ HealthCare Corp.421
  CymaBay Therapeutics, Inc.431
  Daewoong Pharmaceutical Co., Ltd.441
  Esperion Therapeutics, Inc.451
  Golden Biotechnology Corp.461
  HanAll Biopharma Co., Ltd.471
  Hanmi Pharmaceuticals, Co. Ltd.481
  Huons Co., Ltd.491
  Hyundai Pharmaceutical Co., Ltd.501
  Innovent Biologics, Inc.511
  Jeil Pharmaceutical Co., Ltd.521
  Kowa Company, Ltd.531
  Kyorin Pharmaceutical Co., Ltd.541
  LG Life Science LTD.551
  LipimetiX Development Inc561
  Matinas BioPharma Holdings, Inc.571
  Pfizer Inc.581
  Pharmena SA591
  Protalix BioTherapeutics, Inc.601
  Regeneron Pharmaceuticals Inc611
  Sancilio &Company, Inc.621
  Yuhan Corporation631
  Zydus Cadila Healthcare Limited641
Hyperlipidemia Therapeutics Assessment6514
  Assessment by Monotherapy Products651
  Assessment by Combination Products661
  Assessment by Target674
  Assessment by Mechanism of Action714
  Assessment by Route of Administration752
  Assessment by Molecule Type772
Drug Profiles79107
  (amlodipine besylate + atorvastatin calcium + valsartan) Drug Profile791
  (amlodipine besylate + rosuvastatin calcium + valsartan) Drug Profile801
  (atorvastatin calcium + losartan potassium) Drug Profile811
  (atorvastatin calcium + metformin hydrochloride) XR Drug Profile821
  (ezetimibe + rosuvastatin calcium) Drug Profile831
  (gemigliptin + rosuvastatin calcium) Drug Profile841
  (metformin hydrochloride SR + rosuvastatin calcium) Drug Profile851
  AC-261066 Drug Profile861
  AEM-28 Drug Profile872
  AEM-2802 Drug Profile891
  AEM-2814 Drug Profile901
  ALN-AC3 Drug Profile911
  ALN-ANG Drug Profile921
  antroquinonol Drug Profile932
  ARI-3037MO Drug Profile952
  BCWPC-001 Drug Profile971
  bempedoic acid Drug Profile988
  bezafibrate ER Drug Profile1061
  BH-03004 Drug Profile1071
  BioE-1115 Drug Profile1081
  bococizumab Drug Profile1094
  BSN-272 Drug Profile1131
  CAT-2000 Series Drug Profile1141
  CAT-2003 Drug Profile1153
  CDX-085 Drug Profile1182
  centatin Drug Profile1201
  DWJ-1351 Drug Profile1211
  etanercept biosimilar Drug Profile1222
  evolocumab Drug Profile12412
  gemcabene calcium Drug Profile1362
  HOB-071 Drug Profile1381
  HU-012 Drug Profile1391
  IBI-306 Drug Profile1401
  icosabutate Drug Profile1411
  IMMH-007 Drug Profile1421
  ISIS-APOCIIILRx Drug Profile1431
  JS-002 Drug Profile1441
  K-312 Drug Profile1451
  leucine + niacin Drug Profile1461
  LTPO-3FA Drug Profile1471
  MAT-9001 Drug Profile1482
  MBX-8025 Drug Profile1503
  MN-002 Drug Profile1531
  NKPL-66 Drug Profile1544
  Oligonucleotide for Hyperlipidemia and Atherosclerosis Drug Profile1581
  omega-3-carboxylic acids Drug Profile1594
  PF-06427878 Drug Profile1631
  PF-06815345 Drug Profile1641
  Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia Drug Profile1651
  REGN-1001 Drug Profile1661
  saroglitazar Drug Profile1672
  SC-401 Drug Profile1691
  Small Molecule for Atherosclerosis and Hyperlipidemia Drug Profile1701
  Small Molecule for Hyperlipidemia Drug Profile1711
  Small Molecule for Hypertriglyceridaemia Drug Profile1721
  Small Molecule for Type 2 Diabetes and Hyperlipidemia Drug Profile1731
  Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes Drug Profile1742
  Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease Drug Profile1761
  TRIA-662 Drug Profile1772
  volanesorsen sodium Drug Profile1796
  YH-22189 Drug Profile1851
Hyperlipidemia Dormant Projects1869
Hyperlipidemia Discontinued Products1951
Hyperlipidemia Product Development Milestones19612
  Featured News &Press Releases1961
    Jul 11, 2016: Wests SmartDose Drug Delivery Technology Platform Selected by Amgen for Pushtronex System1961
    Jun 28, 2016: Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid1962
    Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions1981
    May 23, 2016: BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders1981
    May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen1991
    May 11, 2016: Cigna s New Value-Based Contract with Amgen for Repatha1991
    May 04, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates2002
    Apr 04, 2016: New study results of Repatha (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association2021
    Apr 03, 2016: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"2021
    Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab2031
    Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia2041
    Mar 21, 2016: Amgen To Present Repatha (Evolocumab) Data At ACC.162052
    Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab)2071
    Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims2071
    Feb 04, 2016: Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha (Evolocumab) In Statin-Intolerant Patients With High Cholesterol2071
Appendix2082
  Methodology2081
  Coverage2081
  Secondary Research2081
  Primary Research2081
  Expert Panel Validation2081
  Contact Us2081
  Disclaimer2091

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hyperlipidemia - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hyperlipidemia-Pipeline-Review-H2-2016-2088-16352>
  
APA:
Global Markets Direct - Market Research. (2016). Hyperlipidemia - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hyperlipidemia-Pipeline-Review-H2-2016-2088-16352>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.